BioD showcasing placental tissue-based product portfolio at 2013 AAOS

Follow @prnewschannel

(PR NewsChannel) / March 15, 2013 / MEMPHIS, Tenn.  

BioD, LLC, a vertically integrated biomedical company engaged in the development and commercialization of novel biologic products derived from the placental tissues, will introduce its BioDGenesis Micronized Tissue Matrix at the 2013 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) on March 19-23 in Chicago, Illinois.  In addition, BioD will be showcasing its entire placental tissue-based product portfolio including BioDfactor, BioDfence, BioDDryflex and AmnioExcel. Conference attendees can visit BioD at Booth #114.

BioDGenesis Micronized Tissue Matrix is a cryopreserved injectable allograft derived from the human placental tissues for use as a wound covering in the treatment of localized areas of joint inflammation or soft tissue injury.  Primarily used in sports medicine applications, BioDGenesis has been developed to cover and protect the wound or localized area of inflammation and to provide a natural scaffold that facilitates the migration and proliferation of the patient’s own cells to the site of injury.

“We are excited to bring our advanced tissue processing technology to the AAOS.  We believe the versatility and regenerative potential of our placental-derived products is an ideal solution for the treatment of many sports medicine injuries.  This meeting is an excellent forum for BioD to present our novel biologic products to the orthopedic medical community,” commented President and CEO, Greg Brophy.  “With over twenty-five patents or provisional patents filed in connection with our proprietary processing techniques and the clinical use of our products, we are committed to developing a complete line of novel tissue-based products that will enhance the quality of patient care in a broad range of clinical applications.”

About BioD: BioD, LLC is a leading regenerative medicine company engaged in the development and commercialization of novel biologic products derived from the placental tissues.  Our research and development efforts are focused on the regenerative potential of amnion and the other placental tissues given their unique biologic structure, their rich source of undifferentiated stem cells, and the unique immune privilege that characterizes their function in the body.  From the recovery of tissue from live, healthy donors during childbirth to the development of new products that will improve patient outcomes, BioD is unlocking the regenerative potential of the human body.  For more information, visit our website at

Darin Gerlach
Vice President Marketing

Forward-looking statement
Any forward-looking statement is based on information available to BioD, LLC as of the date of the statement.  All written or oral forward-looking statements attributable to BioD are qualified by this caution.  BioD does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in BioD’s expectations.

Direct link:


Print FriendlyPrint Friendly

This press release is distributed by PR NewsChannel. Your News. Everywhere.